{"data":[{"accessionNo":"0000919574-26-005481","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001604464","issuerName":"Atara Biotherapeutics, Inc.","ticker":"ATRA","cusip":"046513206","securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2026-06-30","reportingPerson":"Point72 Asset Management, L.P.","reportingCik":null,"personType":"PN","sharesOwned":687718,"percentOfClass":7.6,"filedAt":"2026-08-14","canonicalUrl":"https://xoomar.com/markets/stocks/atra"},{"accessionNo":"0000919574-26-005481","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001604464","issuerName":"Atara Biotherapeutics, Inc.","ticker":"ATRA","cusip":"046513206","securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2026-06-30","reportingPerson":"Steven A. Cohen","reportingCik":null,"personType":"IN","sharesOwned":687718,"percentOfClass":7.6,"filedAt":"2026-08-14","canonicalUrl":"https://xoomar.com/markets/stocks/atra"},{"accessionNo":"0000919574-26-005481","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001604464","issuerName":"Atara Biotherapeutics, Inc.","ticker":"ATRA","cusip":"046513206","securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2026-06-30","reportingPerson":"Point72 Capital Advisors, Inc.","reportingCik":null,"personType":"CO","sharesOwned":687718,"percentOfClass":7.6,"filedAt":"2026-08-14","canonicalUrl":"https://xoomar.com/markets/stocks/atra"},{"accessionNo":"0001104659-26-086728","formType":"SCHEDULE 13D/A","amendmentNo":3,"issuerCik":"0001604464","issuerName":"Atara Biotherapeutics, Inc.","ticker":"ATRA","cusip":"046513206","securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2026-07-22","reportingPerson":"Redmile Group, LLC","reportingCik":"0001425738","personType":"IA,OO","sharesOwned":950994,"percentOfClass":9.9,"filedAt":"2026-07-24","canonicalUrl":"https://xoomar.com/markets/stocks/atra"},{"accessionNo":"0001104659-26-086728","formType":"SCHEDULE 13D/A","amendmentNo":3,"issuerCik":"0001604464","issuerName":"Atara Biotherapeutics, Inc.","ticker":"ATRA","cusip":"046513206","securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2026-07-22","reportingPerson":"Green Jeremy","reportingCik":"0001650527","personType":"IN,HC","sharesOwned":950994,"percentOfClass":9.9,"filedAt":"2026-07-24","canonicalUrl":"https://xoomar.com/markets/stocks/atra"},{"accessionNo":"0001104659-26-086728","formType":"SCHEDULE 13D/A","amendmentNo":3,"issuerCik":"0001604464","issuerName":"Atara Biotherapeutics, Inc.","ticker":"ATRA","cusip":"046513206","securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2026-07-22","reportingPerson":"Redmile Biopharma Investments II, L.P.","reportingCik":"0001772230","personType":"PN","sharesOwned":631020,"percentOfClass":6.6,"filedAt":"2026-07-24","canonicalUrl":"https://xoomar.com/markets/stocks/atra"},{"accessionNo":"0001104659-26-086728","formType":"SCHEDULE 13D/A","amendmentNo":3,"issuerCik":"0001604464","issuerName":"Atara Biotherapeutics, Inc.","ticker":"ATRA","cusip":"046513206","securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2026-07-22","reportingPerson":"Redmile Strategic Long Only Trading Sub, Ltd.","reportingCik":"0002048243","personType":"CO","sharesOwned":401901,"percentOfClass":4.2,"filedAt":"2026-07-24","canonicalUrl":"https://xoomar.com/markets/stocks/atra"},{"accessionNo":"0001104659-26-061506","formType":"SCHEDULE 13D/A","amendmentNo":2,"issuerCik":"0001604464","issuerName":"Atara Biotherapeutics, Inc.","ticker":"ATRA","cusip":"046513206","securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2026-05-12","reportingPerson":"Redmile Group, LLC","reportingCik":"0001425738","personType":"IA,OO","sharesOwned":950994,"percentOfClass":9.9,"filedAt":"2026-05-14","canonicalUrl":"https://xoomar.com/markets/stocks/atra"},{"accessionNo":"0001104659-26-061506","formType":"SCHEDULE 13D/A","amendmentNo":2,"issuerCik":"0001604464","issuerName":"Atara Biotherapeutics, Inc.","ticker":"ATRA","cusip":"046513206","securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2026-05-12","reportingPerson":"Jeremy C. Green","reportingCik":"0001650527","personType":"IN,HC","sharesOwned":950994,"percentOfClass":9.9,"filedAt":"2026-05-14","canonicalUrl":"https://xoomar.com/markets/stocks/atra"},{"accessionNo":"0001104659-26-061506","formType":"SCHEDULE 13D/A","amendmentNo":2,"issuerCik":"0001604464","issuerName":"Atara Biotherapeutics, Inc.","ticker":"ATRA","cusip":"046513206","securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2026-05-12","reportingPerson":"Redmile Biopharma Investments II, L.P.","reportingCik":"0001772230","personType":"PN","sharesOwned":651924,"percentOfClass":6.9,"filedAt":"2026-05-14","canonicalUrl":"https://xoomar.com/markets/stocks/atra"},{"accessionNo":"0001104659-26-061506","formType":"SCHEDULE 13D/A","amendmentNo":2,"issuerCik":"0001604464","issuerName":"Atara Biotherapeutics, Inc.","ticker":"ATRA","cusip":"046513206","securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2026-05-12","reportingPerson":"Redmile Strategic Long Only Trading Sub, Ltd.","reportingCik":"0002048243","personType":"CO","sharesOwned":576148,"percentOfClass":6.1,"filedAt":"2026-05-14","canonicalUrl":"https://xoomar.com/markets/stocks/atra"},{"accessionNo":"0000919574-26-002914","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001604464","issuerName":"Atara Biotherapeutics, Inc.","ticker":"ATRA","cusip":"046513206","securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2026-03-31","reportingPerson":"Adage Capital Management, L.P.","reportingCik":null,"personType":"IA,PN","sharesOwned":700000,"percentOfClass":8.56,"filedAt":"2026-05-13","canonicalUrl":"https://xoomar.com/markets/stocks/atra"},{"accessionNo":"0000919574-26-002914","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001604464","issuerName":"Atara Biotherapeutics, Inc.","ticker":"ATRA","cusip":"046513206","securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2026-03-31","reportingPerson":"Robert Atchinson","reportingCik":null,"personType":"HC,IN","sharesOwned":700000,"percentOfClass":8.56,"filedAt":"2026-05-13","canonicalUrl":"https://xoomar.com/markets/stocks/atra"},{"accessionNo":"0000919574-26-002914","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001604464","issuerName":"Atara Biotherapeutics, Inc.","ticker":"ATRA","cusip":"046513206","securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2026-03-31","reportingPerson":"Phillip Gross","reportingCik":null,"personType":"HC,IN","sharesOwned":700000,"percentOfClass":8.56,"filedAt":"2026-05-13","canonicalUrl":"https://xoomar.com/markets/stocks/atra"},{"accessionNo":"0001193125-26-217389","formType":"SCHEDULE 13D/A","amendmentNo":3,"issuerCik":"0001604464","issuerName":"Atara Biotherapeutics, Inc.","ticker":"ATRA","cusip":"046513107","securityClass":"Common Stock","eventDate":"2026-05-07","reportingPerson":"James Huang","reportingCik":"0001573160","personType":"IN","sharesOwned":1318894,"percentOfClass":16.1,"filedAt":"2026-05-11","canonicalUrl":"https://xoomar.com/markets/stocks/atra"},{"accessionNo":"0001193125-26-217389","formType":"SCHEDULE 13D/A","amendmentNo":3,"issuerCik":"0001604464","issuerName":"Atara Biotherapeutics, Inc.","ticker":"ATRA","cusip":"046513107","securityClass":"Common Stock","eventDate":"2026-05-07","reportingPerson":"Panacea Innovation Limited","reportingCik":"0002010692","personType":"CO","sharesOwned":1318894,"percentOfClass":16.1,"filedAt":"2026-05-11","canonicalUrl":"https://xoomar.com/markets/stocks/atra"},{"accessionNo":"0001193125-26-217389","formType":"SCHEDULE 13D/A","amendmentNo":3,"issuerCik":"0001604464","issuerName":"Atara Biotherapeutics, Inc.","ticker":"ATRA","cusip":"046513107","securityClass":"Common Stock","eventDate":"2026-05-07","reportingPerson":"Panacea Venture Healthcare Fund II GP Company, Ltd.","reportingCik":null,"personType":"CO","sharesOwned":1011000,"percentOfClass":12.4,"filedAt":"2026-05-11","canonicalUrl":"https://xoomar.com/markets/stocks/atra"},{"accessionNo":"0001193125-26-217389","formType":"SCHEDULE 13D/A","amendmentNo":3,"issuerCik":"0001604464","issuerName":"Atara Biotherapeutics, Inc.","ticker":"ATRA","cusip":"046513107","securityClass":"Common Stock","eventDate":"2026-05-07","reportingPerson":"Panacea Venture Healthcare Fund II, L.P.","reportingCik":"0001869939","personType":"PN","sharesOwned":1011000,"percentOfClass":12.4,"filedAt":"2026-05-11","canonicalUrl":"https://xoomar.com/markets/stocks/atra"},{"accessionNo":"0001193125-26-217389","formType":"SCHEDULE 13D/A","amendmentNo":3,"issuerCik":"0001604464","issuerName":"Atara Biotherapeutics, Inc.","ticker":"ATRA","cusip":"046513107","securityClass":"Common Stock","eventDate":"2026-05-07","reportingPerson":"Panacea Opportunity Fund I GP Company, Ltd.","reportingCik":null,"personType":"CO","sharesOwned":307899,"percentOfClass":3.8,"filedAt":"2026-05-11","canonicalUrl":"https://xoomar.com/markets/stocks/atra"},{"accessionNo":"0001193125-26-217389","formType":"SCHEDULE 13D/A","amendmentNo":3,"issuerCik":"0001604464","issuerName":"Atara Biotherapeutics, Inc.","ticker":"ATRA","cusip":"046513107","securityClass":"Common Stock","eventDate":"2026-05-07","reportingPerson":"Panacea Opportunity Fund I, L.P.","reportingCik":"0001869966","personType":"PN","sharesOwned":307899,"percentOfClass":3.8,"filedAt":"2026-05-11","canonicalUrl":"https://xoomar.com/markets/stocks/atra"},{"accessionNo":"0000919574-26-002802","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001604464","issuerName":"Atara Biotherapeutics, Inc.","ticker":"ATRA","cusip":"046513206","securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2026-05-07","reportingPerson":"Point72 Asset Management, L.P.","reportingCik":null,"personType":"PN","sharesOwned":526682,"percentOfClass":6.2,"filedAt":"2026-05-08","canonicalUrl":"https://xoomar.com/markets/stocks/atra"},{"accessionNo":"0000919574-26-002802","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001604464","issuerName":"Atara Biotherapeutics, Inc.","ticker":"ATRA","cusip":"046513206","securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2026-05-07","reportingPerson":"Point72 Capital Advisors, Inc.","reportingCik":null,"personType":"CO","sharesOwned":526682,"percentOfClass":6.2,"filedAt":"2026-05-08","canonicalUrl":"https://xoomar.com/markets/stocks/atra"},{"accessionNo":"0000919574-26-002802","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001604464","issuerName":"Atara Biotherapeutics, Inc.","ticker":"ATRA","cusip":"046513206","securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2026-05-07","reportingPerson":"Steven A. Cohen","reportingCik":null,"personType":"IN","sharesOwned":526682,"percentOfClass":6.2,"filedAt":"2026-05-08","canonicalUrl":"https://xoomar.com/markets/stocks/atra"},{"accessionNo":"0000935836-26-000230","formType":"SCHEDULE 13G/A","amendmentNo":3,"issuerCik":"0001604464","issuerName":"Atara Biotherapeutics, Inc.","ticker":"ATRA","cusip":"046513206","securityClass":"Common Stock","eventDate":"2026-05-07","reportingPerson":"EcoR1 Capital, LLC","reportingCik":null,"personType":"IA,OO","sharesOwned":1552000,"percentOfClass":17.4,"filedAt":"2026-05-07","canonicalUrl":"https://xoomar.com/markets/stocks/atra"},{"accessionNo":"0000935836-26-000230","formType":"SCHEDULE 13G/A","amendmentNo":3,"issuerCik":"0001604464","issuerName":"Atara Biotherapeutics, Inc.","ticker":"ATRA","cusip":"046513206","securityClass":"Common Stock","eventDate":"2026-05-07","reportingPerson":"Oleg Nodelman","reportingCik":null,"personType":"HC,IN","sharesOwned":1552000,"percentOfClass":17.4,"filedAt":"2026-05-07","canonicalUrl":"https://xoomar.com/markets/stocks/atra"},{"accessionNo":"0000935836-26-000230","formType":"SCHEDULE 13G/A","amendmentNo":3,"issuerCik":"0001604464","issuerName":"Atara Biotherapeutics, Inc.","ticker":"ATRA","cusip":"046513206","securityClass":"Common Stock","eventDate":"2026-05-07","reportingPerson":"EcoR1 Capital Fund Qualified, L.P.","reportingCik":null,"personType":"PN","sharesOwned":1445609,"percentOfClass":16.2,"filedAt":"2026-05-07","canonicalUrl":"https://xoomar.com/markets/stocks/atra"},{"accessionNo":"0001193125-26-013362","formType":"SCHEDULE 13D/A","amendmentNo":2,"issuerCik":"0001604464","issuerName":"Atara Biotherapeutics, Inc.","ticker":"ATRA","cusip":null,"securityClass":"Common Stock","eventDate":"2026-01-12","reportingPerson":"Panacea Innovation Limited","reportingCik":"0002010692","personType":"CO","sharesOwned":1632345,"percentOfClass":19.99,"filedAt":"2026-01-14","canonicalUrl":"https://xoomar.com/markets/stocks/atra"},{"accessionNo":"0001193125-26-013362","formType":"SCHEDULE 13D/A","amendmentNo":2,"issuerCik":"0001604464","issuerName":"Atara Biotherapeutics, Inc.","ticker":"ATRA","cusip":null,"securityClass":"Common Stock","eventDate":"2026-01-12","reportingPerson":"James Huang","reportingCik":"0001573160","personType":"IN","sharesOwned":1632345,"percentOfClass":19.99,"filedAt":"2026-01-14","canonicalUrl":"https://xoomar.com/markets/stocks/atra"},{"accessionNo":"0001193125-26-013362","formType":"SCHEDULE 13D/A","amendmentNo":2,"issuerCik":"0001604464","issuerName":"Atara Biotherapeutics, Inc.","ticker":"ATRA","cusip":null,"securityClass":"Common Stock","eventDate":"2026-01-12","reportingPerson":"Panacea Venture Healthcare Fund II, L.P.","reportingCik":"0001869939","personType":"PN","sharesOwned":1324446,"percentOfClass":18.2,"filedAt":"2026-01-14","canonicalUrl":"https://xoomar.com/markets/stocks/atra"},{"accessionNo":"0001193125-26-013362","formType":"SCHEDULE 13D/A","amendmentNo":2,"issuerCik":"0001604464","issuerName":"Atara Biotherapeutics, Inc.","ticker":"ATRA","cusip":null,"securityClass":"Common Stock","eventDate":"2026-01-12","reportingPerson":"Panacea Venture Healthcare Fund II GP Company, Ltd.","reportingCik":null,"personType":"CO","sharesOwned":1324446,"percentOfClass":18.2,"filedAt":"2026-01-14","canonicalUrl":"https://xoomar.com/markets/stocks/atra"},{"accessionNo":"0001193125-26-013362","formType":"SCHEDULE 13D/A","amendmentNo":2,"issuerCik":"0001604464","issuerName":"Atara Biotherapeutics, Inc.","ticker":"ATRA","cusip":null,"securityClass":"Common Stock","eventDate":"2026-01-12","reportingPerson":"Panacea Opportunity Fund I, L.P.","reportingCik":"0001869966","personType":"PN","sharesOwned":307899,"percentOfClass":4.1,"filedAt":"2026-01-14","canonicalUrl":"https://xoomar.com/markets/stocks/atra"},{"accessionNo":"0001193125-26-013362","formType":"SCHEDULE 13D/A","amendmentNo":2,"issuerCik":"0001604464","issuerName":"Atara Biotherapeutics, Inc.","ticker":"ATRA","cusip":null,"securityClass":"Common Stock","eventDate":"2026-01-12","reportingPerson":"Panacea Opportunity Fund I GP Company, Ltd.","reportingCik":null,"personType":"CO","sharesOwned":307899,"percentOfClass":4.1,"filedAt":"2026-01-14","canonicalUrl":"https://xoomar.com/markets/stocks/atra"},{"accessionNo":"0000935836-25-000703","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001604464","issuerName":"Atara Biotherapeutics, Inc.","ticker":"ATRA","cusip":null,"securityClass":"Common Stock","eventDate":"2025-09-30","reportingPerson":"EcoR1 Capital, LLC","reportingCik":null,"personType":"IA,OO","sharesOwned":715853,"percentOfClass":9.9,"filedAt":"2025-11-14","canonicalUrl":"https://xoomar.com/markets/stocks/atra"},{"accessionNo":"0001104659-25-112574","formType":"SCHEDULE 13D/A","amendmentNo":1,"issuerCik":"0001604464","issuerName":"Atara Biotherapeutics, Inc.","ticker":"ATRA","cusip":null,"securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2025-11-12","reportingPerson":"Jeremy C. Green","reportingCik":"0001650527","personType":"IN,HC","sharesOwned":751223,"percentOfClass":9.9,"filedAt":"2025-11-14","canonicalUrl":"https://xoomar.com/markets/stocks/atra"},{"accessionNo":"0001104659-25-112574","formType":"SCHEDULE 13D/A","amendmentNo":1,"issuerCik":"0001604464","issuerName":"Atara Biotherapeutics, Inc.","ticker":"ATRA","cusip":null,"securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2025-11-12","reportingPerson":"Redmile Group, LLC","reportingCik":"0001425738","personType":"IA,OO","sharesOwned":751223,"percentOfClass":9.9,"filedAt":"2025-11-14","canonicalUrl":"https://xoomar.com/markets/stocks/atra"},{"accessionNo":"0000935836-25-000703","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001604464","issuerName":"Atara Biotherapeutics, Inc.","ticker":"ATRA","cusip":null,"securityClass":"Common Stock","eventDate":"2025-09-30","reportingPerson":"Oleg Nodelman","reportingCik":null,"personType":"HC,IN","sharesOwned":715853,"percentOfClass":9.9,"filedAt":"2025-11-14","canonicalUrl":"https://xoomar.com/markets/stocks/atra"},{"accessionNo":"0000935836-25-000703","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001604464","issuerName":"Atara Biotherapeutics, Inc.","ticker":"ATRA","cusip":null,"securityClass":"Common Stock","eventDate":"2025-09-30","reportingPerson":"EcoR1 Capital Fund Qualified, L.P.","reportingCik":null,"personType":"PN","sharesOwned":667639,"percentOfClass":9.3,"filedAt":"2025-11-14","canonicalUrl":"https://xoomar.com/markets/stocks/atra"},{"accessionNo":"0001104659-25-112574","formType":"SCHEDULE 13D/A","amendmentNo":1,"issuerCik":"0001604464","issuerName":"Atara Biotherapeutics, Inc.","ticker":"ATRA","cusip":null,"securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2025-11-12","reportingPerson":"Redmile Biopharma Investments II, L.P.","reportingCik":"0001772230","personType":"PN","sharesOwned":452153,"percentOfClass":6,"filedAt":"2025-11-14","canonicalUrl":"https://xoomar.com/markets/stocks/atra"},{"accessionNo":"0001104659-25-112574","formType":"SCHEDULE 13D/A","amendmentNo":1,"issuerCik":"0001604464","issuerName":"Atara Biotherapeutics, Inc.","ticker":"ATRA","cusip":null,"securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2025-11-12","reportingPerson":"Redmile Strategic Long Only Trading Sub, Ltd.","reportingCik":"0002048243","personType":"CO","sharesOwned":376377,"percentOfClass":5,"filedAt":"2025-11-14","canonicalUrl":"https://xoomar.com/markets/stocks/atra"},{"accessionNo":"0001104659-25-112574","formType":"SCHEDULE 13D/A","amendmentNo":1,"issuerCik":"0001604464","issuerName":"Atara Biotherapeutics, Inc.","ticker":"ATRA","cusip":null,"securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2025-11-12","reportingPerson":"RedCo I, L.P.","reportingCik":"0001813157","personType":"PN","sharesOwned":347442,"percentOfClass":4.7,"filedAt":"2025-11-14","canonicalUrl":"https://xoomar.com/markets/stocks/atra"}],"updatedAt":"2026-11-05T14:30:18.830Z","source":"xoomar.com","docs":"https://xoomar.com/markets/api","license":"https://xoomar.com/terms","attribution":"Credit XOOMAR with a link to the dataset page on xoomar.com when you republish this data","canonicalUrl":"https://xoomar.com/markets/stocks/atra","meta":{"source":"SEC","sourceAttribution":"Schedule 13D and 13G data: SEC.","notice":"10 requests a minute without a key, 30 with a free key. Get a free key at https://xoomar.com/signup?utm_source=api, register your app at https://xoomar.com/developers/register?utm_source=api, and credit the data as \"Data: XOOMAR\" together with the sourceAttribution line."}}